Cirugía General y del Aparato Digestivo, Unidad HBP, Hospital Universitari Mutua Terrassa, Universitat de Barcelona (UB), Terrassa, Barcelona, Spain.
Cirugía General y del Aparato Digestivo, Unidad HBP, Hospital Universitari Mutua Terrassa, Universitat de Barcelona (UB), Terrassa, Barcelona, Spain.
Cir Esp (Engl Ed). 2024 Oct;102(10):540-547. doi: 10.1016/j.cireng.2024.09.003. Epub 2024 Sep 19.
To evaluate the bacterobilia in patients undergoing pancreaticoduodenectomy (PD) based on whether they carry a preoperative biliary drainage or not and to analyse if a targeted perioperative antibiotic treatment based on the expected microbiology leads in no differences in Surgical Site Infections (SSI) between the groups.
Retrospective observational single-center study of patients undergoing pancreaticoduodenectomy with preoperative biliary stent (group P, Prosthesis) and without stent (group NP, No Prosthesis). Postoperative complications including SSI and its subtypes were analyzed after applying a targeted perioperative antibiotic treatment protocol with cefotaxime and metronidazole (group NP) and piperacillin-tazobactam (group P).
Between January 2014 and December 2021, 127 patients were treated (84 in group NP and 43 in group P). Intraoperative cultures were positive in 16.7% (group NP) vs 76.7% (group P, p < 0.01). Microorganisms isolated in group NP included Enterobacterales (10.7%) and Enterococcus spp. (7.1%) with no Candida detected. In group P: Enterobacterales (51.2%), Enterococcus spp. (48.8%), and Candida (16.3%) were higher (p < 0.01%). No differences in morbidity and mortality were observed between the groups. SSI rate was 17.8% in group NP and 23.2% in group P (ns).
Bacterobilia differs in patients with biliary drainage, showing a higher presence of Enterobacterales, Enterococcus spp., and Candida. There were no differences in SSI incidence after applying perioperative antibiotic treatment tailored to the expected microorganisms in each group. This raises the need to reconsider conventional surgical prophylaxis in patients with biliary stent.
评估接受胰十二指肠切除术(PD)的患者是否存在胆汁菌血症,并分析基于预期微生物学的靶向围手术期抗生素治疗是否会导致两组之间手术部位感染(SSI)无差异。
这是一项回顾性观察性单中心研究,纳入了接受胰十二指肠切除术且术前放置胆道支架(P 组,假体)和未放置支架(NP 组,无假体)的患者。术后并发症,包括 SSI 及其亚型,在应用头孢噻肟和甲硝唑(NP 组)和哌拉西林他唑巴坦(P 组)的靶向围手术期抗生素治疗方案后进行分析。
2014 年 1 月至 2021 年 12 月,共治疗了 127 名患者(NP 组 84 名,P 组 43 名)。术中培养阳性率为 16.7%(NP 组)vs. 76.7%(P 组,p<0.01)。NP 组分离出的微生物包括肠杆菌科(10.7%)和肠球菌属(7.1%),未检测到念珠菌。P 组则为肠杆菌科(51.2%)、肠球菌属(48.8%)和念珠菌(16.3%)(p<0.01)。两组患者的发病率和死亡率无差异。NP 组 SSI 发生率为 17.8%,P 组为 23.2%(无统计学差异)。
胆道引流患者的胆汁菌血症存在差异,表现为肠杆菌科、肠球菌属和念珠菌的存在更高。在每组中应用针对预期微生物的围手术期抗生素治疗后,SSI 发生率无差异。这使得有必要重新考虑胆道支架患者的常规手术预防措施。